Good clinical practices in the bioanalytical laboratory
Despite the existence of good clinical practice guidelines, the way in which they are applied to the bioanalytical laboratory remains unclear. Aspects of patient confidentiality, informed consent and subject withdrawal; addressing unblinding associated with sample analysis, including repeat analysis and incurred sample reanalysis; or the differences in responsibilities between the sponsor and contract research organization are not articulated by the US FDA within the bioanalytical setting, and for most bioanalytical laboratories this remains a gap in their standard operating procedures. The aim of this article is to identify and clarify the aspects of the good clinical practices that are applicable to the bioanalytical laboratory when conducting bioanalysis with clinical samples, and to address potential gaps in the bioanalytical laboratory when it comes to clinical sample bioanalysis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Bioanalysis - 15(2023), 22 vom: 09. Nov., Seite 1381-1388 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tudan, Christopher [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Audits |
|---|
| Anmerkungen: |
Date Completed 01.11.2023 Date Revised 01.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/bio-2023-0150 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362337160 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362337160 | ||
| 003 | DE-627 | ||
| 005 | 20231226091027.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2023-0150 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362337160 | ||
| 035 | |a (NLM)37737137 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tudan, Christopher |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Good clinical practices in the bioanalytical laboratory |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.11.2023 | ||
| 500 | |a Date Revised 01.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Despite the existence of good clinical practice guidelines, the way in which they are applied to the bioanalytical laboratory remains unclear. Aspects of patient confidentiality, informed consent and subject withdrawal; addressing unblinding associated with sample analysis, including repeat analysis and incurred sample reanalysis; or the differences in responsibilities between the sponsor and contract research organization are not articulated by the US FDA within the bioanalytical setting, and for most bioanalytical laboratories this remains a gap in their standard operating procedures. The aim of this article is to identify and clarify the aspects of the good clinical practices that are applicable to the bioanalytical laboratory when conducting bioanalysis with clinical samples, and to address potential gaps in the bioanalytical laboratory when it comes to clinical sample bioanalysis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CRO | |
| 650 | 4 | |a audits | |
| 650 | 4 | |a clinical | |
| 650 | 4 | |a confidentiality | |
| 650 | 4 | |a contract research organization | |
| 650 | 4 | |a data integrity | |
| 650 | 4 | |a fit-for-purpose | |
| 650 | 4 | |a informed consent | |
| 650 | 4 | |a protocol | |
| 650 | 4 | |a regulatory | |
| 650 | 4 | |a sponsor | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d 2009 |g 15(2023), 22 vom: 09. Nov., Seite 1381-1388 |w (DE-627)NLM196969840 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:22 |g day:09 |g month:11 |g pages:1381-1388 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/bio-2023-0150 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 22 |b 09 |c 11 |h 1381-1388 | ||